Invent Pharma and Palex: Healthcare M&A June 2016

, , ,
Integral service around a transaction
BY : Diego GutiérrezJuly Thu, 2016
Venture capital firms are boosting the healthcare sector in Spain. This month we learned that Corpfin has bought Palex, a medical device company, to provide it with sufficient liquidity to make acquisitions. In addition, Apax Partners has also invested heavily in the sector and bought Invent Pharma for €220M.

m&a sanitary

Apax Partners buys Invent Pharma for €220M

Invent Farma, a laboratory based in Sant Joan Despí (Baix Llobregat), is changing hands once again. Apax Partners has closed for about €220M the purchase of the pharmaceutical group comprising Laboratorios Lesvi, Inke and Quilaten.

This operation is the first one that the British fund has carried out in Catalonia since 2007, when it took control of Electro Stocks Groupa company dedicated to the professional distribution of electrical, automation, air conditioning and plumbing equipment, in which it now holds the entire share capital.

Invent Farma has its origins in 2004, when Icelandic pharmaceutical entrepreneur Fridrik Steinn Kristjánsson bought industrial assets from the former Catalan group Vita. Kristjánsson divested most of his stake in 2013 in favour of Icelandic funds.

The laboratory manufactures active pharmaceutical ingredients in Castellbisbal (Vallès Occidental) for its own products and for third parties; its customers include European and Japanese pharmaceutical companies.

In recent years, Invent Farma, which employs 430 people, has specialised in niche products, particularly in the respiratory and ophthalmology fields. The company made the leap to the United States in 2015, when it set up its first subsidiary in New Jersey. The subsidiary is focused solely on commercial functions.

Corpfin buys Palex, to give financial muscle to group looking to make acquisitions

The Knuth family, founder and owner of Palex, has decided to sell a majority stake in the healthcare technology group to a private equity fund. Corpfin. The aim of the operation is for Palex to gain financial muscle to embark on a new phase of growth by acquiring companies in the sector and diversifying its business lines. Palex already has several acquisitions on the table and will now rely on Corpfin Capital's expertise in integration and build-up processes.

Headquartered in Sant Cugat del Vallès and with a workforce of 300, the healthcare technology and supplies group operates through ten divisions and markets the products of more than 400 international companies. Palex Medical, which does not manufacture, is particularly strong in technology and instruments for cardiac surgery, such as valves and pacemakers. Orthopaedic surgery is another of its business pillars, along with diagnostics and nephrology. Its star products include a device that allows dialysis to be performed at the patient's home and Oncotype, a predictive test for breast cancer. Werfen, also from Catalonia, is one of its main competitors.

Other posts that may interest you

Inveready bets on biotechnology, invests in Cuantum and AB-biotics in less than a month

Investors lose their fear of investing in biotechnology

Spanish biotech companies go public

If you are looking for financing for your company, contact us. Abra-Invest has a team of experts in alternative financing at your disposal with extensive experience in the biotech sector. Call us on + 34 944240141 or fill in the contact form.

The M&A Professionals

Meet our services



Do you want to be up to date?


Our diferentiation

Market Research Technology
Our team of market analysis specialists is continuously analyzing the investments of the most active markets in the industry in order to unceasingly contribute ideas of the current market situation and identify the most relevant trends for senior management. We integrate the most relevant sources of information which allows us to discover the most interesting companies for venture capital and similarly helps us to identify the investors with the highest probability of involvement in an M&A process to ensure the success of our sell-side operations.

The reports and deductions of our advisors provide a broad view of the sector, both geographically and from the complementary or adjacent markets perspective.
Technology Data Analytics
for M&A
Advanced data anlytics is a weapon". Intelfin is an artificial intelligence tool we use for investing and creating value in SMEs through competitive analytics and the enterprise environment.

IntelFin consists of a cognitive system, which, through the application of advanced analytical technologies, facilitates the automation of investment and financing decisions in the field of non-listed companies and especially SMEs in high-growth sectors.

The information related to these companies is characterized by their lack of transparency and heterogeneity; thus, it is necessary to develop an advanced analysis which is as much predictive as prescriptive and is developed in a natural language custom, suitable to obtain greater clarity and knowledge of the investment scope.

The IntelFin system focuses especially on analyzing the variables that define and influence the competitive environment of a sector and the positioning of a company, analyzing their influence on future value creation. Therefore, IntelFin supports strategic decision-making to senior management by resolving questions such as:

¿What are my competitors' priorities, strategies and expansion plans? Who's my competition? Which competitor is most likely to grow at a higher rate?
Which areas of activity/business models will receive the most investment? Which sectors are most attractive to investors?
Which companies are going to experience the most growth in the near future? Which companies are most likely to receive investment or be acquired?
Training Methodology
We have developed training programs in an innovative set-up which guarantees our teams the acquisition of technical competences both in the field of corporate finance and in the field of psychology, that is much needed when it comes to negotiation processes.

We have a culture of continuous improvement of our processes, closely related to the use of information systems that allow the enhancement of internal communication between our teams, as well as external communication with our customers. Hence, we extend best practices identified internally in an efficient and rapid manner among our members.

Are you one of those who prefer to be well informed when making decisions?